EBV BMLF-1 280-288 (HLA-A*02:01) GLCTLVAML

Order number: P2295.9501
Shipping: shipped at RT, store at -20°C Delivery time: 3- 8 working days
For detailed information on the delivery date, please contact Genaxxon.
Quantity | Unit price |
---|---|
To 2 | €145.00 * |
From 3 | €116.00 * |
Prices plus VAT plus shipping costs
Single peptide (GLCTLVAML) for stimulation of humanEBV BMLF-1(280-288) CD8+ specific CD8+ T-cells.
The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Purities offered: >95%.
T-cell epitopes are presented on the surface of antigen-presenting cells by MHC molecules. T- cell epitopes presented by MHC class I molecules are typically peptides between 8 and 11 amino acids in length and exhibiting MHC-specific sequence motifs.
- Do you have any questions concerning this product?
- Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses.
- Further products by Peptides & Elephants
Technical Data:
Specifications:
Purity: >95% (HPLC, ESi-MS)
Sequence: GLCTLVAML
HLA-type: HLA-A*02:01
lyophilized powder
application:
control peptide for stimulation of IFN gamma release from CD8+ T cellsSource
syntheticSicherheits Hinweise / Safety
Klassifizierungen / Classification
eclass-Nr: 34-16-04-90Dokumente - Protokolle - Downloads
Here you will find information and further literature on EBV BMLF-1 280-288 (HLA-A*02:01) GLCTLVAML. For further documents (certificates with additional lot numbers, safety data sheets in other languages, further product information) please contact Genaxxon biosience at: info@genaxxon.com or phone: +49 731 3608 123.